Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Summary

This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called loncastuximab, linked to a chemotherapy drug, called tesirine. Loncastuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them.

Timeline

Start

2023-08-07

Primary completion

2026-05-05

Completion

2026-05-21

Drugs

Indications